Previous 10 | Next 10 |
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy PR Newswire VYVGART® Hytrulo is the first and only neonatal Fc receptor (FcRn) blocker that is delivered as...
2024-06-21 07:25:03 ET More on Bristol-Myers Squibb Bristol-Myers Squibb: Move Investing Time Horizon To 2025, At Least Bristol-Myers Squibb: Could This Be A Value Trap? (Technical Analysis) Bristol-Myers Squibb Company (BMY) Goldman Sachs 45th Annual Global Healthca...
2024-06-07 10:32:06 ET Summary Halozyme Therapeutics, Inc. raised both its full year 2024 financial guidance and 5-year financial outlook on Thursday, sending the stock 12% higher. Halozyme Therapeutics continues to execute well, is buying back a significant amount of its own stoc...
2024-06-07 09:16:13 ET More on Halozyme Therapeutics Halozyme Therapeutics, Inc. (HALO) Q1 2024 Earnings Call Transcript Halozyme Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics ...
2024-06-07 07:15:04 ET H.C. Wainwright analyst issues BUY recommendation for HALO on June 7, 2024 06:06AM ET. The previous analyst recommendation was Buy. HALO was trading at $51.44 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
2024-06-07 06:00:08 ET Joseph Catanzaro from Piper Sandler issued a price target of $51.00 for HALO on 2024-06-07 05:25:00. The adjusted price target was set to $51.00. At the time of the announcement, HALO was trading at $51.44. The overall price target consensus is at ...
2024-06-06 21:15:02 ET Piper Sandler analyst issues NEUTRAL recommendation for HALO on June 6, 2024 07:30PM ET. The previous analyst recommendation was Overweight. HALO was trading at $51.44 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-06-06 20:00:08 ET Corinne Jenkins from Goldman Sachs issued a price target of $44.00 for HALO on 2024-06-06 18:10:00. The adjusted price target was set to $44.00. At the time of the announcement, HALO was trading at $51.44. The overall price target consensus is at $...
2024-06-06 19:30:03 ET Goldman Sachs analyst issues NEUTRAL recommendation for HALO on June 6, 2024 06:10PM ET. The previous analyst recommendation was Neutral. HALO was trading at $51.44 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cu...
A look at the top 10 most actives in the United States Freight Technologies Inc. (FRGT) rose 10.4% to $0.6899 on volume of 220,478,071 shares Nauticus Robotics Inc. (KITT) rose 23.2% to $0.17 on volume of 217,326,595 shares GameStop Corporation (GME) rose 47.5% to $46.55 on volume of 178,...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...